DrugPatentWatch Database Preview

Wellstat Therap Company Profile

« Back to Dashboard

What is the competitive landscape for WELLSTAT THERAP, and when can generic versions of WELLSTAT THERAP drugs launch?

WELLSTAT THERAP has two approved drugs.

There are two US patents protecting WELLSTAT THERAP drugs.

There are one hundred and seventy-two patent family members on WELLSTAT THERAP drugs in twenty-one countries and two supplementary protection certificates in two countries.

Summary for Wellstat Therap

International Patents:	172
US Patents:	2
Tradenames:	2
Ingredients:	1
NDAs:	2

Drugs and US Patents for Wellstat Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wellstat Therap	VISTOGARD	uridine triacetate	GRANULE;ORAL	208159-001	Dec 11, 2015		RX	Yes	Yes
Wellstat Therap	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes
Wellstat Therap	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes	6,258,795		Y
Wellstat Therap	VISTOGARD	uridine triacetate	GRANULE;ORAL	208159-001	Dec 11, 2015		RX	Yes	Yes	7,776,838

Expired US Patents for Wellstat Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wellstat Therap	VISTOGARD	uridine triacetate	GRANULE;ORAL	208159-001	Dec 11, 2015	5,968,914

Non-Orange Book US Patents for Wellstat Therap

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,103,701	Method for enhancing hematopoiesis with acyl deoxyribonucleosides
6,348,451	Acyl deoxyribonucleoside derivatives and uses thereof
5,736,531	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
7,105,498	Acylated uridine and cytidine and uses thereof

International Patents for Wellstat Therap Drugs

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	8910129
Canada	2193967
Norway	970631
South Korea	100418483

Supplementary Protection Certificates for Wellstat Therap Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0889	Netherlands		PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
2017 00036	Denmark		PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Wellstat Therap